1. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
- Author
-
Sorri I, Brigell MG, Mályusz M, Mahlamäki E, de Meynard C, and Kälviäinen R
- Subjects
- 4-Aminobutyrate Transaminase metabolism, Adolescent, Adult, Aged, Anticonvulsants pharmacology, Anticonvulsants therapeutic use, Epilepsy drug therapy, Female, Humans, Lymphocytes drug effects, Lymphocytes metabolism, Male, Middle Aged, Ornithine-Oxo-Acid Transaminase metabolism, Perceptual Disorders blood, Vigabatrin pharmacology, Vigabatrin therapeutic use, Visual Field Tests, Visual Fields physiology, Young Adult, gamma-Aminobutyric Acid blood, Anticonvulsants adverse effects, Perceptual Disorders chemically induced, Perceptual Disorders enzymology, Vigabatrin adverse effects, Visual Fields drug effects
- Abstract
Background: A gabaergic antiepileptic drug, vigabatrin (VGB), is known to induce bilateral concentric visual field defects (VFD) in 30-40% of treated patients. Although the clinical and electrophysiological features of VFDs are well documented, the mechanism of retinal toxicity is still unclear., Purpose: To determine if low basal ornithine-δ-aminotranspherase (OAT) activity is implicated in the etiology of VGB retinotoxicity, resulting in a phenotype of a mild form of gyrate atrophy., Methods: Assays of OAT activity in lymphocytes and GABA-transaminase activity in platelets were performed, and plasma levels of GABA, ornithine, lysine, glutamic acid and glutamine were measured, and visual fields were examined. A total of 47 subjects, aged 14-78 years, were examined. Twenty-one epileptic patients were off VGB more than 1 year; 11 patients with VGB-induced VFD and 10 with normal visual fields. Ten epileptic patients were on current VGB therapy more than 1 year; four patients with VGB-induced VFD and six with normal visual fields. The results were compared with those of 10 epilepsy patients taking tiagabine and six patients who suffered from gyrate atrophy (GA) or were obligate carriers of the disease., Results: In patients who had stopped VGB and who had VFDs, OAT activity was significantly reduced as compared with those who had normal visual fields (77.4pmol P5C/min/mgPro vs. 181.9pmol P5C/min/mgPro, p=0.002). In patients with ongoing VGB therapy, no difference was found between the patients with and without VFDs (149.4pmol P5C/min/mgPro vs. 159.1pmol P5C/min/mgPro)., Conclusions: : The results suggest that VGB retinotoxicity might be associated with elevated retinal ornithine mediated by low basal OAT activity., (Copyright © 2010 Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF